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Abstract
This chapter explores the relationship between the genes and proteins of the Akt and 
MAPK pathways and autism. This chapter presents the biology of these two pathways, 
their genes and cascading proteins, and then, it looks at the research that has connected 
these molecules to autism. Finally, it imparts current and future therapeutic modalities 
that might exploit abnormalities in these genes and proteins, change them and ultimately 
alter aberrant autistic behaviors.
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1. Introduction
In this chapter, we will review (1) the biology of intracellular pathways, with particular 
emphasis on the Akt and the MAPK pathways, (2) the potential association of Akt and MAPK 
pathway markers and autism, and (3) current and potential therapy as it might be related to 
these pathways.
This chapter is not a review of all pathways and biomarkers in cells, but, instead, the focus 
is on two prominent pathways, the Akt and MAPK, known to play a role in the etiology of 
autism.
© 2017 The Author(s). Licensee InTech. This chapter is distributed under the terms of the Creative Commons
Attribution License (http://creativecommons.org/licenses/by/3.0), which permits unrestricted use,
distribution, and reproduction in any medium, provided the original work is properly cited.
2. The biology of the Akt and MAPK intracellular pathways
2.1. Structure and function of intracellular pathways associated with autism
2.1.1. Receptors and ligands
Intracellular pathways are initiated by ligands, such as growth factors, which attach to receptor 
proteins embedded in cell membranes (Figure 1). The stimulation of a pathway receptor initiates 
the pathway signaling that ultimately results in changes in DNA transcription and/or translation, 
and effects processes such as cell division, protein production, cell morphology and motility.
Two receptor proteins [epidermal growth factor receptor (EGFR) and c‐Met (also called MET 
or hepatocyte growth factor receptor)], and their respective ligands [epidermal growth factor 
(EGF) and hepatocyte growth factor (HGF)] (Figure 1), will be reviewed here. Both of these 
receptor/ligand pairs have been found to initiate the Akt and MAPK pathways and have been 
implicated in the etiology of autism.
2.1.2. EGFR and EGF
EGFR is a glycoprotein that is a member of the protein kinase superfamily [1], and there‐
fore is one of the receptor tyrosine kinases (RTKs). Binding of the receptor protein to the 
ligand, EGF, induces receptor dimerization, which stimulates its intracellular protein tyro‐
sine kinase activity. As a result, there is autophosphorylation of several tyrosine (Y) residues 
in the C‐terminal domain of EGFR [2]. This autophosphorylation causes downstream activa‐
tion and signaling by several other proteins that react with the phosphorylated tyrosines. 
Figure 1. Membrane receptor [receptor tyrosine kinase (RTK)], either cMET or epidermal growth factor (EGFR) is 
signaled by growth factor (GF), either HGF or EGF, respectively. The interaction leads to phosphorylation inside the cell.
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The downstream signaling proteins initiate several signal cascades or pathways, principally 
the MAPK and Akt pathways [3]. These activated pathway proteins may lead to DNA syn‐
thesis, cell proliferation, cell migration, adhesion and proliferation [3].
Human EGF is a small 6045‐Da protein [4] with 53 amino acid residues and three intramolecular 
disulfide bonds [5]. EGF acts by binding with high affinity to epidermal growth factor receptor 
(EGFR) on the cell surface. This stimulates ligand‐induced receptor dimerization [6].
2.1.3. cMET and HGF
c‐Met, or MET, is a membrane receptor protein that also possesses tyrosine kinase activity [7] 
and, therefore, is also a RTK. This cell surface receptor is expressed in epithelial cells of many 
organs, including the liver, pancreas, prostate, kidney, muscle and bone marrow, during both 
embryogenesis and adulthood [8]. c‐MET has been shown to interact directly with the epi‐
dermal growth factor receptor (EGFR), allowing activation of c‐MET after stimulation of cells 
with EGF [9, 10].
The ligand for c‐MET is hepatocyte growth factor (HGF) [11, 12]. It is secreted as a single inac‐
tive polypeptide and is cleaved by serine proteases into a 69‐kDa alpha‐chain and a 34‐kDa 
beta‐chain. A disulfide bond between the alpha and beta chains produces the active, heterodi‐
meric molecule [13].
HGF, through its signaling of c‐MET, has been found to regulate cell growth, cell motility and 
morphogenesis through its activation of the c‐Met receptor [14].
2.1.4. Downstream MAPK and AKT pathways
Stimulation of RTKs by EGF or HGF begins the downstream cascade of activated pathway 
proteins. The cascade starts when a signaling molecule (i.e., EGF or HGF) binds to the RTK 
on the cell surface. The pathways are chains of proteins that activate each other in a cascade 
fashion. A protein in the pathway is inactive, until it is phosphorylated by another protein in 
the cascade. Once it is activated, it can then catalyze the next substrate (protein) in the pathway. 
Overall, the proteins communicate a signal from the receptor on the membrane to the DNA in 
the nucleus. The DNA, through protein translation, orchestrates a change in the cell, such as 
increasing or decreasing cell division, cell morphology or cell motility.
2.1.5. Downstream MAPK pathway
The mitogen‐activated protein kinases (MAPK) pathway (Figure 2) may begin with binding 
of EGF to EGFR. This activates the tyrosine kinase activity of the portion of the receptor in the 
cytoplasm. Docking proteins such as GRB2 (growth factor receptor‐bound protein 2) contain 
an SH2 domain that binds to the phosphotyrosine residues of the activated receptor [15]. 
GRB2 then binds to the guanine nucleotide exchange factor Son of Sevenless (SOS) by way of 
the two SH3 domains of GRB2. When the GRB2‐SOS complex docks to phosphorylated EGFR, 
SOS becomes activated [16]. (SOS was inactivated until it binds to activated EGFR, hence the 
cascade begins.) Activated SOS then promotes the removal of GDP from a member of the Ras 
subfamily (most notably H‐Ras (transforming protein p21) or K‐Ras (V‐Ki‐ras2 Kirsten rat 
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sarcoma viral oncogene homolog). Ras can then bind guanosine‐5′‐triphosphate (GTP) and 
become active. Activated Ras activates the protein kinase activity of RAF (proto‐oncogene ser‐
ine/threonine‐protein kinase) kinase [17]. RAK kinase then phosphorylates MEK1 and MEK2 
(mitogen‐activated protein kinase kinase). MEK then phosphorylates and activates mitogen‐
activated protein kinase (MAPK), also known as extracellular signal‐regulated kinases (ERK).
MAPK regulates the activities of several transcription factors. It can phosphorylate factor 
MYK, which plays a role in cell cycle progression, apoptosis and cellular transformation [18], 
and it can phosphorylate and activate MNK (interacting protein kinases), which, in turn, 
phosphorylates cAMP response element‐binding protein (CREB). CREB has a well‐docu‐
mented role in neuronal plasticity and long‐term memory [19] (Figure 2).
2.1.6. Downstream AKT pathway
The Akt pathway also starts with stimulation by a growth factor (i.e., EGF). This causes activation 
of a cell surface receptor (i.e., EGFR) and phosphorylation of phosphatidylinositol 3‐kinase (PI3K) 
(Figure 3). Activated PI3K then phosphorylates lipids on the plasma membrane, forming second 
messenger PIP
3
 (phosphatidylinositol (3,4,5)‐trisphosphate). Akt, a serine/threonine kinase, is 
recruited to the membrane by interaction with these docking sites, so that it can be fully activated 
[20] (Figure 3).
Activated Akt causes downstream activation, which, by phosphorylating a range of intracellular 
proteins, ultimately results in changes in cell survival, growth, proliferation, cell migration and/
or angiogenesis.
Figure 2. The MAPK pathway may begin with a growth factor (EGF or HGF) binding to the membrane RTK (cMET or 
EGFR). A cascade of activation ensues when the cytoplasmic portion of the RTK is phosphorylated, which, in turn, reacts 
with GRB2. At the end of the cascade, a transcription such as CREB affects protein production.
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The downstream effects of the Akt pathway are thoroughly regulated. The pathway is negatively 
regulated by phosphatase and tensin homolog (PTEN), which antagonizes PI3K. Demonstrated 
by the fact that loss of PTEN function leads to over‐activation of Akt [21], the Akt pathway, in 
turn, regulates PTEN levels by activating transcription factors such as nuclear factor kappa‐
light‐chain‐enhancer of activated B cells (NF‐κB). These factors activate PTEN agonists, such as 
tumor necrosis factor alpha (TNFα), which, in turn, suppress PTEN [22].
Once it is activated, Akt interacts with its many substrates. As examples, Akt can phosphorylate 
Bcl‐2‐associated death promoter (BAD) causing it to lose its pro‐apoptotic function, and promote 
cell survival [23]. Under various circumstances, activation of Akt has been shown to overcome 
cell cycle arrest in the G1 [24] and G2 [25] phases. Once activated, it can also affect cell division by 
Figure 3. The Akt pathway may begin with a growth factor (EGF or HGF) binding to the membrane RTK (cMET or 
EGFR). A cascade of activation ensues when the cytoplasmic portion of the RTK is phosphorylated, which, in turn, reacts 
with P13K. At the end of the cascade, pathway proteins such as mTOR and GSK3 are affected.
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activating the transcription factor CREB [26], inhibiting the enzyme inhibitor p27 (cyclin‐depen‐
dent kinase inhibitor 1B) [27], localizing the transcription factor, forkhead box class O (FOXO) in 
the cytoplasm [27], activating the membrane lipid, phosphatidylinositol (PtdIns)‐3ps [28], and 
activating the kinase mechanistic target of rapamycin (mTOR) [25], which can affect transcrip‐
tion of p70 or eukaryotic initiation factor 4E binding protein 1 (4EBP1) [27]. Glycogen synthase 
kinase 3 (GSK‐3) is inhibited upon phosphorylation by Akt. This results in an increase in glyco‐
gen synthesis [29]. Akt also enhances pathological angiogenesis and tumor growth associated 
with abnormalities in skin and blood vessels [25, 30].
2.2. Other biomarkers related to MAPK or Akt pathways
2.2.1. Oxytocin
There is evidence suggesting that oxytocin (OXT) is a regulator of the PI3K/Akt/mTORC1 
pathway in gut cells and may, therefore, modulate translation in these cells [31].
The MAPK pathway is thought to be upregulated in the paraventricular (PVN) nuclei during 
lactation, and many of OXT's effects in peripheral and brain tissue are mediated through a 
MAPK/ERK pathway. Data also suggest an enhanced activation of the MAPK/ERK pathway 
in OXT neurons, specifically during late pregnancy in both the SON and PVN [32].
2.2.2. GABA
There is also evidence suggesting a relationship between the Akt pathway and GABA trans‐
mission. This relationship may be important in glucose metabolism and B cell proliferation. In 
human islets, GABA activates a calcium‐dependent signaling pathway through both GABA‐A 
and GABA‐B receptors. This, in turn, activates the P13K‐Akt and CREB‐IRS‐2 signaling path‐
ways that convey GABA signals responsible for β‐cell proliferation and survival [33].
The MAPK pathway may be a negative modulator of GABA‐A receptor function [34]. Also, 
baicalin, a flavone glycoside, which modulates MAPK, has been found to have neuroprotective 
properties as a sedative associated with altering GABAergic signaling [35].
3. Association between pathway genes, proteins and autism
3.1. Genes associated with autism
Twin studies suggest that autism is highly heritable [36, 37], but there has not been just one 
gene associated with the etiology of the disorder(s). This could be because the majority of 
genes linked to autism are related to a specific symptom. Instead, not one, but many genes 
that are known to play a role in brain development are candidates for conferring susceptibility 
to autism.
According to the Simons Foundation Autism Research Initiative (SFARI) (Updated June, 
2016), there are more than 800 genes implicated in autism, with annotations and links to 
published papers [38, 39]. The SAFARI gene‐scoring module offers critical evaluation of the 
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strength of the evidence for each gene's association with autism, with at least 50 high‐ranking 
candidate risk genes so far identified.
We will be focusing here on only a few of the high‐ranking autism‐associated gene candidates, 
with particular emphasis on genes related to the Akt and MAPK pathways.
3.2. Pathway genes
MET (met proto‐oncogene) encodes the hepatocyte growth factor receptor. MET, which has 
tyrosine kinase activity. Positive associations between MET and autism have been found in the 
Caucasian, Japanese and Italian populations as well as in Autism Genetic Resource Exchange 
(AGRE) family cohorts from multiple studies [40–42]. Interestingly, a positive association has 
also been found between MET and schizophrenia [43]. There is evidence to suggest that MET 
variances and MET/AKT interaction may affect facial emotion perception, implicating that the 
MET/AKT cascade plays a significant role in facial emotion perception [44].
Phosphatase  and tensin homolog (PTEN) gene encodes a phosphatidylinositol‐3,4,5‐trispho‐
sphate 3‐phosphatase, which contains a tensin‐like domain, as well as a catalytic domain simi‐
lar to that of the dual specificity protein tyrosine phosphatases. Several studies have found 
rare single variations in the PTEN gene associated with autism [45–47], including in Cowden 
syndrome [48], where some individuals with the syndrome develop autism.
Engrailed homeobox 2 (EN2) is a homeobox gene that is critical to the development of the 
midbrain and cerebellum [49]. It regulates the combined processes of cell division, differen‐
tiation and organ development. Four candidate gene studies have explored the relationship 
between EN2 and autism—three found a positive association.
Reelin (RELN) gene produces an extracellular matrix protein with serine protease activity [50], 
which is responsible for correct lamination of the brain during the embryonic period and cell 
signaling and synaptic plasticity in adult life [51]. Deficits in brain levels of Reelin mRNA and 
protein have been found in subjects with schizophrenia and bipolar disorder [52], as well as 
major depression [53] and autism [54]. Genetic studies show an association of polymorphisms 
in the RELN gene in autism [55, 56]. Reelin has recently been shown to activate Akt, as well as 
Src family kinases, suggesting a relationship between Reelin and the Akt pathway [57].
GABA‐A receptor, BETA‐3 polypeptide (GABRB3) encodes the GABA receptor. GABA is the 
main inhibitory neurotransmitter in the adult brain. During neurotransmission, GABA activates 
the GABA‐A receptor. Data suggest that rare variants of GABRB3 might be associated with 
autism, and increased GABRB3 expression may contribute to the pathogenesis of autism in some 
patients [58]. Insulin‐induced translocation of GABA‐ARs to the cell surface requires activation of 
Akt, a primary target of insulin signaling downstream of PI3K. Akt phosphorylates a conserved 
phosphorylation site present in all three b subunits of GABA‐ARs, which increases cell surface 
expression of these receptors [59, 60].
Fragile X mental retardation 1 (FMR1) mutations are associated with a substantial degree of 
increased risk of autism and are consistently associated with additional features not required 
for an ASD diagnosis [61]. The fragile X mental retardation protein (FMRP), the gene product 
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of FMR1, is an RNA‐binding protein that negatively regulates translation in neurons. The Akt 
pathway is affected by this protein, which is demonstrated by the data that show that mTOR 
phosphorylation and activity are elevated in the hippocampus of juvenile FMR1 knockout 
mice [62].
Neurfibromin 1 (NF1): Genetic association has been found between the NF1 gene and autism. 
In particular, positive association was found with a NF1 polymorphism in the Japanese 
population [63]. The NF1‐encoded protein, neurofibromin, functions as a Ras‐GTPase acti‐
vating protein, and the Akt/mTOR pathway is tightly regulated by neurofibromin [64]. 
Neurofibromatosis type 1 (NF1) is an autosomal dominant neurocutaneous syndrome, resulting 
from functional inactivation of the NF1 gene. Identification of SPRED1 gene mutations in 
individuals with mild NF1‐like syndrome, and the direct involvement of these proteins in the 
RAS‐MAPK pathway, potentially links the action of the NF1 gene to this pathway [65].
Tuberous sclerosis 1 (TSC1): This gene has been associated with syndromic autism, where 
a subpopulation of individuals with tuberous sclerosis syndrome develop autism [66]. This 
gene encodes a growth inhibitory protein thought to play a role in the stabilization of tuberin, 
and the protein has been implicated as a tumor suppressor. Akt and protein kinase B (PKB) 
both regulate and are regulated by the TSC1‐TSC2 complex by interacting with and regulating 
mTOR [67].
Tuberous sclerosis 2 (TSC2): In addition to this gene's association with TSC1, its association 
with autism has also been found in an AGRE cohort [68], and a rare mutation in TSC2 has 
been identified in an individual with ASD [69].
Protein tyrosine kinase 7 (PTK7) is a gene strongly enriched for variants likely to affect ASD 
risk [70]. This gene encodes a member of the receptor protein tyrosine kinase family of pro‐
teins that transduce extracellular signals across the cell membrane. This protein may be asso‐
ciated with inhibition of cell proliferation, invasion and migration by inactivation of AKT and 
ERK [71].
Forkhead box P1 (FOXP1): Studies have found that rare mutations in this gene are associated 
with autism [72], and there is considerable evidence that FOXP1 protein expression is regulated 
by a PI3K/Akt/p70S6K signaling cascade [73].
SH3 and multiple ankyrin repeat domains 3 (SHANK3): Several studies have found rare single‐
gene variations in the SHANK3 gene in autism [74, 75]. However, Italian IMGSAC and Chinese 
Han studies claimed to find no genetic association or rare variations in the SHANK3 gene in 
autistic patients [76]. Pharmacological activation of Akt, and inhibition of CLK2, relieves synaptic 
deficits in SHANK3‐deficient, as well as PMDS patient‐derived, neurons. This suggests a strong 
relationship between SHANK3 and the Akt pathway [77].
Ubiquitin‐protein ligase E3A (UBE3A) produces ubiquitin‐protein ligase (E6AP) that is 
involved in targeting proteins for degradation within cells [78]. Mutations in the UBE3A gene 
are found in patients with Angelman syndrome (AS) [79]. AS is characterized by impaired 
motor and cognitive development, sleep disturbance, clumsy gait, seizures and irregular 
behaviors such as flapping and bursts of laughter. There is a phenotypic overlap between 
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autism and AS, and dysregulation of UBE3A may play a role in the causation of autism [80]. 
UBE3A functions as a co‐activator to regulate PI3K‐Akt signaling pathway [81].
NHE9 (SLC9A9) is an endosomal cation/proton antiporter with orthologues in yeast and 
bacteria. Rare, missense substitutions in NHE9 are genetically linked to autism, but have not 
been functionally evaluated. Loss‐of‐function mutations in NHE9 may contribute to autistic 
phenotype by modulating synaptic membrane protein expression and neurotransmitter clear‐
ance [82]. In addition, endosomal NHE9 is mechanistically involved in the pathophysiology 
of autism [83]. Specifically, in glioblastoma cells, altered NHE9 blocks proton leakage from 
endosomes, causing them to become more acidic. This changes the transportation dynamics of 
proteins in the cell [98]. Epidermal growth factor receptor (EGFR) signaling is a potent driver 
of glioblastoma, a malignant and lethal form of brain cancer. Data demonstrate that endolyso‐
somal pH is critical for receptor sorting and turnover. By functioning as a leak pathway for pro‐
tons, the Na+/H+ exchanger NHE9 limits luminal acidification to circumvent EGFR turnover 
and prolongs downstream signaling pathways [84].
MECP2 Rett syndrome (RTT), a neurodevelopmental disorder that commonly involves 
autism, is caused by mutations in this gene. The expressed protein, MECP2, is important for 
nerve cell maturation and both activates and represses transcription [85].
It should be recognized that the genes represented here are a small representation of the 
hundreds of de novo and familial risk genes, copy number variants, and epigenetic modifiers 
have been identified through linkage analysis, genome‐wide association studies and exon 
and whole‐genome sequencing of individuals with autism over the past few years [86–89].
3.3. Biomarkers associated with autism
3.3.1. Growth factors
3.3.1.1. EGF
An increased frequency of EGF single‐nucleotide polymorphisms has been reported in chil‐
dren with autism [90]. Lower plasma EGF levels have been found in adults with autism [91], 
as well as in children [92, 93]. But these data appear to be uncertain, as one report of younger 
children with autism showed increased levels of EGF [94]. Our lab found reduced levels of 
EGF in an autistic group, and these decreased levels were associated with the inflammatory 
marker HMGB1 and severity of hyperactivity in individuals with autism [94].
3.3.1.2. HGF
Decreased serum levels of HGF were found in male adults with high‐functioning autism [95]. 
Our lab found HGF decreased in the serum of older autistic children with co‐occurring GI 
disease when compared to non‐autistic children with GI disease, autistic children without 
GI disease and healthy controls (non‐autistic children without GI disease) [96]. The c‐Met 
promoter variant rs1858830 reflects a common single‐nucleotide polymorphism that increases 
the risk of ASD and is distinctively associated with ASD in individuals with co‐occurring 
GI dysfunction [97]. These data strongly suggest that decreased MET function is due to the 
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ASD‐associated common genetic variant rs1858830, which predisposes a subset of ASD indi‐
viduals that exhibit GI problems. These results may be one reason for the association between 
gastrointestinal issues and autism [98].
3.3.2. Receptors
3.3.2.1. EGFR
Our lab measured soluble EGFR in individuals with autism. We found that EGFR levels were 
significantly higher in the autism group. These receptor levels also correlated significantly 
with the inflammatory marker HMGB1 and several autism behavioral symptoms, including 
hyperactivity [99]. We found that EGF levels (described above) also correlated significantly 
with HMGB1 and hyperactivity severity. This helps to confirm a possible etiological relation‐
ship between the receptor (EGFR) and its ligand (EGF). In glioblastoma cells, when researchers 
administered drugs that countered NHE9 proteins (above), as well as drugs that countered 
EGFR proteins, the cells were more readily killed, compared to cells that were only treated with 
EGFR‐countering medication [84]. This suggests a relationship between NHE9 and EGFR, and, 
also, if EGFR is elevated, in autism, and this elevation is associated with the etiology of autism, 
it might represent an important way to lower EGFR levels.
3.3.2.2. cMET
c‐MET/HGF signaling is directly related to HGF expression via a positive feedback mecha‐
nism A polymorphism in the upstream region of the hepatocyte growth factor receptor, c‐Met, 
identified in a study involving 1231 autistic children plus appropriate controls [100], shows 
a deficiency in c‐Met protein level which corresponds to reduced transcription rate, as well 
as a downregulation of HGF production [101, 102]. Also, MET receptor protein expression is 
decreased in the postmortem brain of individuals with the MET ‘C’ allele [103], which further 
substantiates its association with the etiology of autism.
3.3.3. MAPK and Akt pathway proteins
3.3.3.1. MAPK proteins
Recent advances in autism genetics and progress in the study of animal models have pro‐
vided evidence suggesting that Akt and MAPK pathway proteins are adversely affected in 
individuals with autism [104]. Genome‐wide association studies [105] and genomic copy 
number variant (CNV) analyses have identified enrichment in gene sets involved in RAS (rat 
sarcoma)/MAPK signaling and kinase activation in ASD individuals [106]. It has been sug‐
gested in an animal model that activation of this pathway in peripheral lymphocytes may 
serve as a marker for central nervous system (CNS) ERK activity, and possibly autistic behav‐
ior [107], and there is evidence of developmental abnormalities in neurogenesis and behav‐
ioral impairment associated with the 16p11.2 chromosomal deletion, which is associated with 
ERK dysregulation [108]. Therefore, disruption of the ERK (MAPK) signaling pathway may 
be an important mediator of abnormal social behavior in individuals with autism.
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In a mouse model, researchers found a significant association between juvenile social behavior 
and phosphorylated mitogen‐activated protein kinase (p‐Mek) and p‐Erk levels in the prefron‐
tal cortex, but not in the cerebellum [105]. Others found that neuronal cell differentiation and 
maturation, and unchanged apoptosis, are associated with the presence of amplified Mapk/
Erk, although these data have since been retracted [109]. However, other studies have demon‐
strated that decreased Mapk/Erk activation can also disrupt stem cell proliferation [110–112] 
and may be associated with autistic behavior. This conflict suggests that dysregulation of the 
MAPK/ERK pathway may be associated with separate autism subpopulations, such that some 
populations have over‐activation of MAPK, and others are characterized by lower activation.
The Kyoto Encyclopedia of Genes and Genomes (KEGG) Pathway Database lists an array 
of highly associative genes associated with the MAPK/ERK pathway that are likely major 
contributors to ASD pathophysiology [113].
3.3.4. Akt proteins
3.3.4.1. Akt
Akt and mTOR, as well as related pathway proteins, have been found to be decreased in autis‐
tic groups [114]. Full‐length PI3K, Akt and phosphorylated and total mTOR were reduced in 
the fusiform gyrus of a small group of autistic individuals [115]. Our lab has found signifi‐
cantly decreased levels of phosphorylated Akt in individuals with autism, and these low Akt 
levels correlated significantly with high EGFR and low GABA [116]. The low Akt levels in this 
study also correlated with high symptom severity. Our results suggest that the Akt pathway, 
starting with aberrant EGFR signaling, and followed by dysfunctional downstream Akt, may 
be involved in the etiology of autism.
3.3.4.2. PTEN
The gene for PTEN, the phosphatase that suppresses P13K/AKT signaling, is mutated in 
a small percentage of autistic individuals. In one study, all PTEN mutations from cases of 
PHTS (hamartoma tumor syndrome) appeared to disrupt the ability to inhibit AKT sig‐
naling, at the same time that PTEN expression was significantly reduced [117]. Inherited 
dominant PTEN mutations have been identified in patients with Cowden syndrome and 
Bannayan‐Riley‐Ruvalcaba syndrome, conditions that are often grouped together as PTEN 
hamartoma tumor syndrome (PHTS) [118], and inhibition of mTORC1 with the inhibitor 
rapamycin suppresses anatomical and behavioral abnormalities in PTEN knockout mice, 
suggesting a strong relationship between mTOR and PTEN [119], as well as an association 
with the etiology of autism.
3.3.4.3. MECP2
This protein, which is deficient in RETTs, may regulate PTEN expression with the help of a spe‐
cific miRNA, miR‐137. Conversely, PTEN can indirectly regulate MECP2 via the transcription 
factor, CREB and miR‐132 [120].
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3.3.4.4. mTOR
Significant decreases in protein expression and phosphorylation of mTOR, as well as compo‐
nents of its downstream signaling pathways, have been found in autism [121]. When mTOR 
is disrupted or decreased, downstream, effectors of protein translation are also reduced [122]. 
Mutations in TSC1, TSC2, NF1 and PTEN lead to an over‐activated PI3K‐mTOR pathway, 
as well as autism‐relevant behaviors, tuberous sclerosis, neurofibromatosis and/or macro‐
cephaly [123]. PI3K‐mTOR signaling is also over‐activated at synapses of fragile X syndrome 
(FXS) mice [124] and in humans with FXS [125]. mTOR signaling and protein synthesis are 
also impaired in a mouse model of Rett syndrome [126, 127]. Our lab found significantly high 
mTOR levels in individuals with autism, and these high levels correlated significantly with 
decreased oxytocin [128]. These data, collectively, suggest that mTOR may serve as a good 
marker for subgroups of individuals with autism.
3.3.4.5. TSC1 and TSC2
Tuberous sclerosis complex (TSC) is an autosomal dominant disorder caused by mutations 
in either the TSC1 or TSC2 gene [122, 129]. Tsc1+/− and Tsc2+/− mice, both male and female, 
exhibit deficient social interaction, which is reversed by pharmacological inhibition of mTOR 
with rapamycin [130], demonstrating the strong relationship between TSC and mTOR.
4. Potential therapy for autism associated with Akt and MAPK pathway 
alteration of genes and/or proteins
4.1. Akt pathway
As outlined above, mutations in PTEN, NF1 or in the TSC 1 and 2, cause an over‐activation 
of the PI3K/Akt/mTOR pathway, leading to autism‐related behavior. Furthermore, fragile X 
syndrome (FXS), a common inherited form of mental retardation and the leading cause of 
autism, has been associated with over‐activation of the PI3K‐mTOR pathway. On the other 
hand, low levels of PI3K/Akt/mTOR activity are linked with Rett syndrome (RTT), a rare form 
of autism‐associated disease. These data suggest that therapy designed to alter these pathway 
genes and/or proteins may be affective at altering autistic behaviors.
On the basis of observations that mTOR signaling, synaptic plasticity and protein translation are 
over‐activated in these disorders, compounds that can potentially inhibit the mTOR pathway 
represent promising therapeutic candidates.
However, under‐activation of this pathway has been reported in RTT. So, when developing 
therapy for RETTs, it may be important to use therapy that will raise mTOR levels.
Because mTOR has been found to be both high and low, depending on the syndrome, it is pos‐
sible that altered mTOR levels may be associated with certain ASD behaviors and/or subpopu‐
lations, and therefore may provide a means for subgrouping those in the autistic spectrum.
For mTOR over‐activation, the mTORC1 inhibitor rapamycin has shown promising results 
in PTEN KO mice [119] and TSC2 mice [131]. Other inhibitors of mTOR have been tried. 
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For instance, treatment of Fmr1 (protein of fragile X syndrome) knockout mice with temsiro‐
limus, an mTOR inhibitor, prevented object recognition memory deficits and reduced audio‐
genic seizure susceptibility in mice [132].
Elevated phosphorylation of translational control molecules and exaggerated protein synthe‐
sis in fragile X mice were corrected through the targeting of S6K1 (ribosomal protein S6 kinase 
beta‐1 (S6K1), also known as p70S6 kinase (p70S6K)), a serine/threonine kinase that acts 
downstream of PIP3 and targets the S6 ribosomal protein. Deletion of S6K1 prevents a broad 
range of fragile X phenotypes, including exaggerated translation and abnormal dendritic 
spine morphology [133]. Also, targeting downstream mTOR signaling, such as eukaryotic 
translation initiation factor 4E (eIF4E), reversed autism [122]. Thus, interventions that target 
mTOR signaling should be at the leading edge of future translational research for autism.
GSK3 (isoforms GSK3α and GSK3β) is a serine/threonine kinase that is controlled by inhibitory 
serine phosphorylation induced by both Akt and MAPK pathways [134]. In Fmr1 knockout 
mice, GSK3 phosphorylation was reduced in several brain regions, resulting in elevated GSK3 
signaling [135]. Lithium is a GSK3 inhibitor that both increases the inhibitory serine phos‐
phorylation of GSK3 and directly inhibits GSK3 activity [136, 137]. Particularly with chronic 
administration, in Fmr1 knockout mice, lithium was found to be able to correct abnormal 
behavior, such as hyperactivity [138]. Also, specific GSK3 inhibitors SB216763 141, TDZD‐8 
and VP0.7 corrected hippocampus‐dependent learning deficits in fragile X mice [139, 140].
RTT is characterized by loss of function of the X‐linked MECP2 gene [141]. Multiple studies, using 
different knockout mouse models, indicate that the pathological deficit in RTT is associated with 
the structure and function of synapses, synaptic transmission and plasticity [142, 143]. BDNF, 
the gene encoding the BDNF protein, is one of the first recognized direct targets of MECP2 tran‐
scriptional regulation [144]. BDNF, through the receptor tropomyosin‐related kinase B (TrkB), 
activates intracellular signaling cascades, Akt and MAPK, critical for neuronal development, 
synaptic maturation, and learning and memory [145]. Therefore, one direction of potential ther‐
apy for MECP2 deficiency is the trial and use of drugs that boost BDNF. Compounds that boost 
BDNF levels such as fingolimod and glatiramer acetate (copaxone), both FDA‐approved drugs 
for the treatment of multiple sclerosis, lead to an increase in BDNF expression and activation of 
TrkB/Akt downstream signaling pathways [146].
Insulin growth factor‐1 (IGF‐1) binds to the IGF‐1 receptor and also activates intracellular sig‐
naling cascades, similar to those triggered by BDNF activation of TrkB receptors, by modulat‐
ing synaptic plasticity and neuronal maturation through PI3K‐Akt and MAPK pathways [147]. 
Unlike BDNF, IGF‐1 permeability through the blood‐brain barrier makes it an attractive com‐
pound for therapy. Based on these promising leads, a phase 2 double‐blind placebo‐controlled 
clinical trial is underway to treat 3‐ to 10–year‐old RTT patients with full‐length IGF‐1 [148].
4.2. MAPK pathway
ERK levels, for the most part, are decreased in autism. Different classes of antidepressants 
rapidly increase ERK [149] and CREB [150] activity. This supports the involvement of the 
MAPK pathway in autism and may suggest the need to develop alternative therapies that 
increase ERK levels.
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Supplemental zinc, which has been found to increase ERK levels, has an antidepressant‐
like effect. This zinc activity may be dependent on the activation of ERK and PI3K/GSK3β 
pathways [151].
4.3. Neurotransmitters
Multiple studies have documented low levels of neurotransmitters (dopamine, 5‐HT, nor‐
adrenaline) in autopsy RTT brains and in MECP2‐deficient mice [152]. Desipramine, an 
antidepressant that blocks the uptake of noradrenaline and has been shown to reverse the 
depletion of tyrosine hydroxylase in the brainstem, helps the regulation of breathing and 
extending the life span of male MECP2 knockout mice [153].
The NMDA‐type of glutamate receptor is altered in MECP2 knockout mice [154], and the 
FDA‐approved NMDA receptor antagonist ketamine has been useful in improving RTT‐like 
phenotypes in MECP22 knockout mice [155].
Studies have shown that GABAergic signaling is also impaired in MECP2‐deficient mice [156], 
and selective deletion of MECP2 in GABAergic neurons has led to impaired GABAergic trans‐
mission, cortical hyperexcitability and several neurological features of RTT and autism [157]. 
Vigabatrin is an antiepileptic drug that irreversibly inhibits GABA transaminase, inhibits GABA 
catabolism and thereby increases GABA levels. The drug is already FDA approved for use 
in epilepsy syndromes. Our lab has shown that decreased Akt levels are associated with low 
GABA [116], suggesting that therapy designed to increase Akt levels may also increase GABA.
4.4. Oxytocin
The neuropeptide oxytocin (OXT), a natural brain peptide produced in the hypothalamus, 
has been implicated in the pathophysiology and possibly the etiology of autism [158]. There 
is a significant association of a sequence variant in the OXT receptor gene with Asperger's 
syndrome [159]. However, the molecular mechanisms underlying the role of OXT in autism 
remain unclear. Recent studies have shown that OXT plays an important role in reducing 
behavioral deficits in an ASD‐like mouse model, mediated by inhibiting the ERK signaling 
pathway and its downstream proteins [160]. OXT increases the salience of social stimuli, pro‐
motes parental nurturing and social bonds and, therefore, has received considerable attention 
as a potential treatment for social deficits in autism. Recent studies in mice have demonstrated 
that a mutation in Cntnap2 (the gene that encodes contactin‐associated protein‐like 2), which, 
in humans, may result in autism, displays robust social deficits and reduced brain OXT. In 
this model, daily intranasal OXT treatment improved later social engagement [161].
Acute intranasal OXT may temporarily enhance social cognition, empathy and reciprocity in 
individuals with autism [160]. In a recent small double‐blind study, those taking OXT spray 
therapy had significantly reduced autism core symptoms specific to social reciprocity [162]. 
However, other recent clinical trials have yielded mixed results [161, 163].
Recent studies suggest that, in addition to its role in the brain, OXT may also have an impor‐
tant neuromodulatory role in the gut by activating the PI3K/Akt pathway in a dose‐ and 
time‐dependent manner [164]. Our lab has found decreased plasma oxytocin in individuals 
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with autism, and these oxytocin levels correlated with high mTOR, suggesting a possible 
relationship between oxytocin and aberrant Akt pathway signaling [128].
In summary, because of the diversity of autism symptoms and behaviors, it is likely that 
drugs, based on altering genes or proteins of the Akt and/or MAPK pathways, will be most 
effective after biomarker screening. Marker screening may also provide an opportunity to 
identify and study subgroups of individuals with autism.
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